CoChat

The Cost Effectiveness of Statin Therapies in Spain in 2010, after the Introduction of Generics and Reference Prices

Plans-Rubió, Pedro · 2010 · American Journal Cardiovascular Drugs

The DOI matches its Crossref record; 72 of the 74 references it cites were found in a registry or an index.

Abstract

Background HMG-CoA reductase inhibitors (statins) are the first-line drugs for use in the reduction of low-density lipoprotein cholesterol (LDL-C) levels and prevention of coronary heart disease (CHD) in patients with hypercholesterolemia. Generic statins could change the cost effectiveness of statin therapies in Spain, and more population groups could be included in the recommendations for reduction of cholesterol levels based on cost effectiveness.Objectives The objectives of this study were: (i) to assess the cost effectiveness of available statins for the reduction of LDL-C levels in Spain in 2010, after the introduction of generics and reference prices; (ii) to assess the cost effectiveness of combination therapy using a statin plus cholestyramine or ezetimibe; and (iii) to estimate the mean cost per patient to achieve National Cholesterol Education Program (Adult Treatment Panel-III) therapeutic objectives.Methods The following treatments were evaluated: rosuvastatin 5-20 mg/day; atorvastatin, simvastatin, and pravastatin 10-40 mg/day; lovastatin and fluvastatin 20-80 mg/day; and combination therapy with a statin plus either cholestyramine 12-24 g/day or ezetimibe 10 mg/day. The cost effectiveness was evaluated in terms of cost per percentage point reduction in LDL-C, comparing the annual treatment costs with the effectiveness in reducing LDL-C. Treatment costs included those for medications (2010 wholesale prices), control measures, and treatment of adverse drug effects. The effectiveness of statins was estimated by developing a meta-analysis of clinical trials published between 1993 and 2005 that met several inclusion criteria. Average and incremental cost-effectiveness ratios were calculated to assess the efficiency of individual statin and combination therapies in reducing LDL-C levels.Results The effectiveness in terms of percentage reduction in LDL-C ranged from 19% for pravastatin 10 mg/day to 55% for atorvastatin 80 mg/day. Annual treatment costs ranged from Euro 189.7 for simvastatin 10 mg/day to Euro 759.3 for atorvastatin 80 mg/day. The cost-effectiveness ratios, in terms of cost per percentage point reduction in LDL-C, were: Euro 6 for simvastatin, Euro 10-12 for rosuvastatin, Euro 10 for lovastatin, Euro 13-16 for atorvastatin, Euro 13-14 for fluvastatin, and Euro 14-20 for pravastatin. Rosuvastatin + ezetimibe, simvastatin + ezetimibe, and atorvastatin + ezetimibe were the most cost-effective combination therapies for reducing LDL-C levels. Rosuvastatin was the most cost-effective statin for achieving the LDL-C therapeutic goal in patients at high risk for CHD, with a mean cost per patient of Euro 516. Simvastatin was the most cost-effective statin to achieve the LDL-C goal in patients with moderate or low CHD risk, with a cost per patient of Euro 217 and Euro 190, respectively.Conclusion Rosuvastatin should be the first-choice agent in patients with high CHD risk, while simvastatin should be the first choice in patients with moderate or low risk. The addition of ezetimibe to rosuvastatin, simvastatin, or atorvastatin should be the preferred combination therapies when greater LDL-C reductions are required. The cost effectiveness of all statin therapies has increased in Spain after the introduction of generic statins and reference prices.

Overview

Integrity signals

Registry

Crossref · 10.2165/11539150-000000000-00000

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 72 references

Research works printed but not linked: 9

  1. Tran, 2007, Can J Clin Pharmacol, 14, 205
  2. Plans Rubió, 2003, Clin Invest Arterioscl, 15, 43
  3. 2008, Informacion Terapeutica del Sistema Nacional de Salud, 32, 99
  4. 2004, Informacion Terapeutica del Sistema Nacional de Salud, 28, 121
  5. Harinder, 2007, Drugs, 61, 1835
  6. Illingworth, 1994, Clin Ther, 16, 366
  7. Farmer, 1992, Clin Ther, 14, 708
  8. Castano, 2002, Int J Clin Pharmacol Res, 22, 89
  9. 2006, Boletin de Coyuntura, 11, 1

Cited by

See all 34

Metadata

Authors
Plans-Rubió, P.
Affiliations
Departament de Salut (ES)
Corresponding author
Plans-Rubió, Pedro
Venue
American Journal Cardiovascular Drugs
Published
2010-12
Volume
10
Issue
6
Pages
369-382
ISSN
1175-3277 (ISSN-L)
OpenAlex
W2068685076
Cited by
31
References
74
Citations by year
2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2019: 1 · 2018: 1 · 2017: 5 · 2016: 8 · 2015: 1 · 2014: 1 · 2013: 3 · 2012: 4
FWCI
3.03
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Cardiovascular Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
statins, cost-effectiveness, LDL cholesterol lowering, hypercholesterolemia, generic drugs, reference prices, combination therapy, ezetimibe, cholestyramine, atorvastatin, simvastatin, pravastatin, rosuvastatin, fluvastatin, lovastatin, Spain
MeSH terms
Ezetimibe, Azetidines, Cholestyramine Resin, Coronary Disease, Cost-Benefit Analysis, Drug Therapy, Combination, Humans, Cholesterol, LDL, Spain, Time Factors, Drugs, Generic, Health Care Costs, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Cost Effectiveness of Statin Therapies in Spain in 2010, after the Introduction of Generics and Reference Prices. https://app.cochat.ai/papers/10.2165/11539150-000000000-00000
The paper
Plans-Rubió, P. (2010). The Cost Effectiveness of Statin Therapies in Spain in 2010, after the Introduction of Generics and Reference Prices. American Journal Cardiovascular Drugs. https://doi.org/10.2165/11539150-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.